title: Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.
abstract: OBJECTIVE
  MicroRNA-126 (miR-126) facilitates angiogenesis and regulates endothelial cell function. Recent data suggest that miR-126 can serve as a biomarker for vascular disease. Although endothelial cells are enriched for miR-126, platelets also contain miR-126. In this paper, we investigated the contribution of platelets to the pool of miR-126 in plasma of patients with type 2 diabetes (DM2) and how this is affected by aspirin.
  
  
  RESULTS
  In vitro platelet activation resulted in the transfer of miR-126 from the platelet to the plasma compartment, which was prevented by aspirin. In vivo platelet activation, monitored in patients with DM2 by measuring soluble P-selectin, correlated directly with circulating levels of miR-126. The administration of aspirin resulted both in platelet inhibition and concomitantly reduced circulating levels of platelet-derived microRNAs including miR-126.
  
  
  CONCLUSIONS
  Platelets are a major source of circulating miR-126. Consequently, in patho-physiological conditions associated with platelet activation, such as diabetes type 2, the administration of aspirin may lead to reduced levels of circulating miR-126. Thus, the use of platelet inhibitors should be taken into account when using plasma levels of miR-126 as a biomarker.
authors: Department of Nephrology and the Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
authors: Hetty C
authors: HC
authors: de Boer
authors: Coen
authors: C
authors: van Solingen
authors: Jurriën
authors: J
authors: Prins
authors: Jacques M G J
authors: JM
authors: Duijs
authors: Menno V
authors: MV
authors: Huisman
authors: Ton J
authors: TJ
authors: Rabelink
authors: Anton Jan
authors: AJ
authors: van Zonneveld
mesh_terms: D000704:Analysis of Variance; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin; D015415:Biomarkers / Q000378:metabolism; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis*; D003925:Diabetic Angiopathies / Q000175:diagnosis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D019007:P-Selectin / Q000378:metabolism; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D015415:Biomarkers; C527111:MIRN126 microRNA, human; D035683:MicroRNAs; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor; D016718:Arachidonic Acid; D001241:Aspirin
keywords: aspirin; diabetes mellitus type 2; miR-126; platelets